-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

Benzinga·12/26/2025 11:10:03
語音播報
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.